# Enspryng

NDC: 50242-007
Generic name: Satralizumab
Labeler / Manufacturer: Genentech, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: SUBCUTANEOUS
Marketing started: 20200814

FDA application: BLA761149

## Active ingredients

- SATRALIZUMAB: 120 mg/mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"50242-007"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=50242-007
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64c156a4-9bad-4d45-a294-0733c141f47b